$JBL

Tyagarajan N. V. purchased $150K of JBL

Tyagarajan N. V. purchased 500 shares of JABIL INC (JBL) at $299.63 ($0.15M total) on 2026-07-17.

Original reporting
SEC EDGAR · Tyagarajan N. V.
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$JBL
Bullish
low confidence
Mentioned
$JBL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JBLBullishLow
01

Why it matters

A director open-market purchase was reported, but the filing does not include new guidance, contracts, litigation, or operational updates.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to materially change valuation without additional fundamental catalysts.

03

What to watch

The article provides no context on the director’s prior trading cadence, compensation, or whether the purchase was part of broader personal liquidity planning.

Relevance 5/10Novelty 3/10Timing: Form 4 filed 2026-08-05, covering a 2026-07-17 purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for Jabil (JBL).

Company-level read

Ticker impact

$JBLBullishLow confidence
Context

Jabil disclosed a director open-market purchase of 500 shares at about $299.63 on 2026-07-17 via a Form 4 filed 2026-08-05.

Expected impact

Likely limited near-term impact; any effect is more sentiment than fundamentals.

Evidence & confidence

The filing is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No clear sector read-through from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may not signal a change in outlook, especially when the transaction size is modest.

Key entities

  • Jabil Inc

    Subject of the Form 4 insider transaction disclosure.

  • Tyagarajan N. V.

    Director who purchased 500 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AKAMHighAI 9/10

Anthropic signs US$11.6 billion cloud deal with Akamai, gets warrant for up to 5% stake

Anthropic agreed to a US$11.6 billion cloud services deal with Akamai, including a warrant for up to 5% stake. Akamai shares rose 20% in extended trading. The 7-year contract involves purchasing Series B shares at US$111.33 each, converting to 7.7 million common shares. Akamai expects US$5.5 billion in capital expenditure and US$1.7 billion increase in 2026 spending.

$JBLMed

Why Jabil (JBL) Shares Are Plunging Today

Jabil (JBL) shares fell 5.1% after Goldman Sachs lowered its price target to $375, citing a more cautious valuation. The stock is volatile, down 22% from its 52-week high, but up 25.1% year-to-date. Higher bond yields and oil prices pose risks for the company.

$JBLMed

JBL Stock Rises as Goldman Sachs Backs AI Growth Story

Jabil Inc. (JBL) stock rose 5.65% after strong earnings guidance. Goldman Sachs, while cutting its target to $375, expects 50% AI revenue growth and 6% EBIT margins. JBL reported $8.75B revenue, $275M net income, and 3% profit margin. The stock is in an uptrend, with support at $300 and resistance around $340.

$JBLMedAI 8/10

Jabil Rises 36.2% Year to Date: Should You Buy the Stock?

Jabil Inc. (JBL) has risen 36.2% year-to-date, outperforming its industry and the S&P 500. The company expects AI-related revenues to reach $13.6B in fiscal 2026, up from $9B in 2025, and is expanding manufacturing capacity to meet demand. JBL also sees growth in healthcare, renewable energy, and digital commerce sectors, but faces supply chain and competition challenges.

$JBLHighAI 8/10

FDA Contamination Warning Could Be A Game Changer For Jabil’s (JBL) Pharma Ambitions

The FDA issued a warning to Jabil's Pharmaceutics International facility, citing significant violations of sterile drug manufacturing practices, including fungal contamination and weak quality oversight. This raises concerns about Jabil's ability to manufacture sterile products and could impact its pharmaceutical expansion plans. Jabil's 2026 revenue guidance of $35 billion includes contributions from healthcare and pharma, which may now be questioned by investors.

$JBLHighAI 8/10

Jabil Stock: Is Wall Street Bullish or Bearish?

Jabil Inc. (JBL), a $33.8B electronic manufacturing services provider, reported Q3 2026 adjusted EPS of $3.16 and revenue of $8.75B, exceeding expectations. The company raised its fiscal 2026 guidance, citing strong AI data-center demand and new partnerships. Shares have surged 58.6% over 52 weeks, outperforming the S&P 500. Analysts rate it a 'Strong Buy' with a mean price target of $451.18.